Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15197166 | 0.94 | ALDH1A1 (0.47) | USP2ALDH1A1TSHRGAACYP3A4 | |
| SCHEMBL694471 | 0.92 | MEN1 (0.49) | ALDH1A1GAACYP3A4MEN1KMT2A | |
| SCHEMBL694272 | 0.90 | MEN1 (0.52) | TSHRCYP3A4MEN1KMT2ACYP2C19 | |
| SCHEMBL694657 | 0.90 | MEN1 (0.51) | ALDH1A1GAACYP3A4MEN1KMT2A | |
| SCHEMBL693369 | 0.90 | MEN1 (0.47) | ALDH1A1GAACYP3A4MEN1KMT2A | |
| SCHEMBL12693460 | 0.88 | KMT2A (0.50) | ALDH1A1CYP3A4MEN1KMT2ACYP2C19 | |
| SCHEMBL694277 | 0.87 | KMT2A (0.56) | ALDH1A1GAACYP3A4MEN1KMT2A | |
| SCHEMBL15197160 | 0.86 | TBXA2R (0.47) | ALDH1A1GAACYP3A4MEN1KMT2A | |
| SCHEMBL15197162 | 0.86 | MEN1 (0.48) | ALDH1A1GAACYP3A4MEN1KMT2A | |
| SCHEMBL694020 | 0.86 | CACNA1H (0.46) | USP2ALDH1A1TSHRCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2502921-B1 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS INC (US) | 2015-05-20 | — | — | EP | disclosed |
| EP-2502921-B1 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS INC (US) | 2015-05-20 | — | — | EP | disclosed |
| US-8658642-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20130217687-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-8420639-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| EP-2502921-A1 | Arylsulfonamide CCR3 antagonists | Axikin Pharmaceuticals, Inc. (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2502921-A1 | Arylsulfonamide CCR3 antagonists | Axikin Pharmaceuticals, Inc. (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2421838-A2 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | Axikin Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20100273795-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| WO-2010123960-A2 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010123960-A2 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273795-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | USP2 1309/4885ALDH1A1 2454/4885TSHR 2517/4885 |
| US-20130217687-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | USP2 1309/4885ALDH1A1 2454/4885TSHR 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.